WELLESLEY, Mass., Jan. 30 /PRNewswire-FirstCall/ -- Coley Pharmaceutical Group, Inc. , today announced that Robert L. Bratzler, Ph.D., President and Chief Executive Officer will present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference in New York on Tuesday, February 6, 2006 at 11:00 a.m. EST.
Interested parties may access an audio webcast of the presentation by visiting the Coley Pharmaceutical Group website at http://www.coleypharma.com. A replay of the webcast will be archived on the "Investor Events" page in the Investor Center section of the Coley website for two weeks until February 20, 2007.
About Coley Pharmaceutical Group
Coley Pharmaceutical Group, Inc. is an international biopharmaceutical company, headquartered in Wellesley, Massachusetts, USA, that discovers and develops TLR Therapeutics(TM), a new class of investigational drug candidates that direct the human immune system to fight cancers, infectious diseases and respiratory disorders. Coley has established a pipeline of TLR Therapeutic product candidates currently advancing through clinical development with partners and has additional product candidates in preclinical development. Coley has product development, research and license agreements with Pfizer, sanofi-aventis, Novartis Vaccines & Diagnostics (formerly Chiron), GlaxoSmithKline and the United States government. For further information on Coley Pharmaceutical Group please visit www.coleypharma.com.
Coley Pharmaceutical Group, Inc.CONTACT: Susan Hager, Senior Director, Investor Relations and CorporateCommunications, of Coley Pharmaceutical Group, +1-781-431-9079 orshager@coleypharma.com, or Media, Karen L. Bergman, +1-650-575-1509, orkbergman@bccpartners.com, or Michelle Corral, +1-415-794-8662, ormcorral@bccpartners.com, both of BCC Partners (US), for ColeyPharmaceutical Group
Web site: http://www.coleypharma.com/
